Check out your Company Bowl for anonymous work chats.
DeepCure is hiring! We are looking for talent to join our team in the US, Israel, and Greece. Learn more and apply below.
A Boston-based biotech company is the latest player to enter the artificial intelligence (AI)-driven drug discovery space. On Monday, DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was founded in 2018.
Boston AI-focused biotech DeepCure closed a $40 million Series A, according to a company announcement this morning — adding more than five times the amount of money the company had before: from $7 million raised since the company’s founding in 2018 to $47 million total. Their goal? To have an R&D process that has drugs fully designed, synthesized and tested by AI, according to a company statement.
Drugmaker DeepCure Snares $40 Million DeepCure and other biotechs aim to accelerate drug discovery with artificial intelligence
DeepCure: The pioneering biotechnology company is coming to Greece with new jobs.
DeepCure joins MIT STEX25 Accelerator.
DeepCure Closes $40M Series A Funding Led by Morningside Ventures
